Linked Life Data

15902961

Source:http://linkedlifedata.com/resource/pubmed/id/15902961

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-5-20
pubmed:abstractText
We have demonstrated, by using a T-cell transfer murine colitis model, that blocking interleukin 6 (IL-6) signaling with monoclonal antibody (mAb) to IL-6 receptor (IL-6R) abrogated apoptosis resistance of lamina propria T cells, suppressed the expression of vascular adhesion molecules, and successfully prevented and treated intestinal inflammation. Based on these results, we carried out an exploratory clinical trial to investigate the safety and efficacy of humanized anti-IL-6R mAb, MRA, in patients with Crohn's disease (CD). The results were promising, with 80% of the patients given every-2-week MRA infusions for 12 weeks showing a significantly higher clinical response rate as compared to 31% of the placebo-treated patients. Twenty percent of the patients on this regimen went into remission as compared to 0% of the placebo group. The acute-phase responses were normalized by a single MRA infusion, which strongly suggests IL-6 is the major cytokine responsible for their production in CD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0944-1174
pubmed:author
pubmed:issnType
Print
pubmed:volume
40 Suppl 16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
32-4
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Treatment of Crohn's disease with anti-IL-6 receptor antibody.
pubmed:affiliation
Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial